



INTEGRATING MOLECULAR ONCOLOGY IN THE CARE OF PATIENTS WITH RARE ONCOGENE-DRIVEN NON-SMALL CELL LUNG CANCER

Chairs

Noemí Reguart, Barcelona, Spain Jürgen Wolf, Cologne, Germany

SUNDAY, 22 OCTOBER 2023

18:30 - 20:00 CEST, HALL 7 - OVIEDO AUDITORIUM

18:30	Welcome and introduction	Noemí Reguart, Barcelona, Spain
18:40	The importance of next-generation sequencing (NGS) testing in non-small cell lung cancer: Science, implementation and timing	Albrecht Stenzinger, Heidelberg, Germany
19:00	The availability of molecular testing in Europe and its implications for state-of-the-art care for patients with lung cancer	Arnaud Bayle, Villejuif, France
19:20	Targeting molecular aberrations beyond EGFR and ALK: Clinical evidence for efficacy and ongoing research	Jürgen Wolf, Cologne, Germany
19:40	Q&A and discussion	All speakers
19:55	Concluding remarks	Jürgen Wolf, Cologne, Germany

This educational activity is provided by ESMO and supported by Eli Lilly and Company.

